Sphingosine 1-Phosphate Regulates Obesity and Glucose Homeostasis
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25020932 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Kazuo Kajita und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health and Nutrition, Faculty of Home Economics, Gifu Women's University, 80 Taromaru, Gifu 501-2592, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin Resistance, Lysophospholipids. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, JSPS.
Abstract (Originalsprache)
One of the major global health and welfare issues is the treatment of obesity and associated metabolic disorders, such as type 2 diabetes mellitus and nonalcoholic fatty liver disease. Obesity, caused by the excessive accumulation of triglycerides in adipose tissues, induces adipocyte dysfunction, followed by inflammation, in adipose tissues and lipotoxicity in nonadipose tissues. Several studies have shown that obesity and glucose homeostasis are influenced by sphingolipid mediators, including ceramide and sphingosine 1-phosphate (S1P). Cellular accumulation of ceramide impairs pancreatic β-cell survival, confers insulin resistance in the liver and the skeletal muscle, and deteriorates adipose tissue inflammation via unknown molecular mechanisms. The roles of S1P are more complicated, because there are five cell-surface S1P receptors (S1PRs: S1P1–5) which have altered functions, different cellular expression patterns, and inapparent intracellular targets. Recent findings, including those by our group, support the notable concept that the pharmacological activation of S1P1 or S1P3 improves obesity and associated metabolic disorders, whereas that of S1P2 has the opposite effect. In addition, the regulation of S1P production by sphingosine kinase (SphK) is an essential factor affecting glucose homeostasis. This review summarizes the current knowledge on SphK/S1P/S1PR signaling in and against obesity, insulin resistance, and associated disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health and Nutrition, Faculty of Home Economics, Gifu Women's University, 80 Taromaru, Gifu 501-2592, Japan.
- Department of Health Chemistry, Showa Pharmaceutical University, 3-3165 Higashitamagawagakuen, Machida 194-8543, Japan.
- Department of General Medicine and General Internal Medicine, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan.
ORCID-Profile: Isao Ishii, Motochika Asano, Hiroyuki Morita
Förderung
- Japan Society for the Promotion of Science
- JSPS
Zitieren
APA
Kajita, K., Ishii, I., Mori, I., Asano, M., Fuwa, M., & Morita, H. (2024). Sphingosine 1-Phosphate Regulates Obesity and Glucose Homeostasis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25020932
Vancouver
Kajita K, Ishii I, Mori I, Asano M, Fuwa M, Morita H. Sphingosine 1-Phosphate Regulates Obesity and Glucose Homeostasis. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25020932
BibTeX
@article{Kajita2024,
author = {Kajita, Kazuo and Ishii, Isao and Mori, Ichiro and Asano, Motochika and Fuwa, Masayuki and Morita, Hiroyuki},
title = {Sphingosine 1-Phosphate Regulates Obesity and Glucose Homeostasis},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25020932}
}
EUVIMED